

Amarantus Bioscience Holdings, Inc.  
Form 8-K  
January 14, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 14, 2014**

**AMARANTUS BIOSCIENCE HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

**333-148922**

**26-0690857**

(State or other jurisdiction of incorporation or organization) (Commission File Number)

IRS Employer

Identification No.)

**c/o Janssen Labs @QB3**

**953 Indiana Street**

**San Francisco, CA**

**94107**

(Address of Principal Executive Offices) (Zip Code)

**(408) 737-2734**

(Registrant's telephone number, including area code)

**675 Almanor Ave**

**Sunnyvale, CA 94085**

(Former name or former address, if changes since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Item 8.01 Other Events**

On January 14, 2014, Amarantus BioScience Holdings, Inc. (the “Company”) released a press release announcing that it has completed the in-licensure of levadopa-induced Dyskinesia Phase 2b-ready Eltoprazine from PsychoGenics.. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information disclosed under this Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

### **Item 9.01 Financial Statements and Exhibits.**

#### ***(d) Exhibits***

<b>Exhibit No.</b>	<b>Description</b>
--------------------	--------------------

99.1	Amarantus Bioscience Holdings, Inc. Press Release, dated January 14, 2014.
------	--

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**AMARANTUS BIOSCIENCE  
HOLDINGS, INC.**

Date: January 14, 2014 By: */s/ Gerald E. Commissiong*  
Name: Gerald E. Commissiong  
Title: Chief Executive Officer